Weekly Investment Analysts’ Ratings Changes for Opus Genetics (IRD)

Opus Genetics (NASDAQ: IRD) recently received a number of ratings updates from brokerages and research firms:

• 10/6/2026 – Opus Genetics had its price target raised by JonesTrading from $10.00 to $17.00. They now have a “buy” rating on the stock.
• 10/4/2026 – Opus Genetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/2/2026 – Opus Genetics had its “buy” rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.
• 9/26/2026 – Opus Genetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/10/2026 – Opus Genetics had its price target raised by Wedbush from $10.00 to $13.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Opus Genetics had its price target raised by Chardan Capital from $13.00 to $16.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Opus Genetics had its price target raised by Oppenheimer Holdings, Inc. from $10.00 to $20.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Opus Genetics had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
• 9/9/2026 – Opus Genetics had its “buy” rating reaffirmed by BTIG Research. They now have a $12.00 price target on the stock.
• 9/9/2026 – Opus Genetics had its “buy” rating reaffirmed by Chardan Capital. They now have a $13.00 price target on the stock.
• 8/16/2026 – Opus Genetics was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling at Opus Genetics

In other Opus Genetics news, CEO George Magrath sold 9,475 shares of Opus Genetics stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total transaction of $27,951.25. Following the sale, the chief executive officer owned 1,731,869 shares of the company’s stock, valued at $5,109,013.55. The trade was a 0.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 556,000 shares of the company’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $4.96, for a total transaction of $2,757,760.00. Following the completion of the sale, the director directly owned 3,236,171 shares of the company’s stock, valued at $16,051,408.16. The trade was a 14.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 613,331 shares of company stock worth $2,971,509. 11.70% of the stock is owned by company insiders.

Opus Genetics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, a group of rare disorders that can cause progressive vision loss and blindness. The company’s research is centered on therapies intended to address the underlying genetic causes of these conditions rather than treating only their symptoms.

Opus Genetics is advancing an investigational pipeline of adeno-associated virus-based gene therapy candidates for diseases involving mutations in genes important to retinal function.